251
|
Mohren M, Daikeler T, Engel A, Guenaydin I, Koetter I. [Diagnosis of the antiphospholipid syndrome in anticoagulated patients]. Z Rheumatol 2004; 63:490-4. [PMID: 15605215 DOI: 10.1007/s00393-004-0593-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2003] [Accepted: 11/19/2003] [Indexed: 11/26/2022]
Abstract
The antiphospholipid syndrome is characterized by thromboembolic events and/or recurrent miscarriages in the presence of anticardiolipin antibodies and/or a lupus anticoagulant. Anticardiolipin antibodies are detected by ELISA whereas lupus anticoagulant detection includes a variety of coagulometric tests. However, a large number of patients with suspected antiphospholipid syndrome are anticoagulated with either heparin or coumadin when evaluated for the presence of a lupus anticoagulant and false positive test results may ensue, thus making coagulometric testing unreliable in this situation. Modifications of standard coagulometric tests have been suggested in order to circumvent this problem and studies of several patient cohorts have shown that the majority of patients with the antiphospholipid syndrome are anticardiolipin positive. However diagnosis in patients receiving anticoagulation remains a difficult task.
Collapse
Affiliation(s)
- M Mohren
- Klinik für Hämatologie/Onkologie, Universität Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
| | | | | | | | | |
Collapse
|
252
|
de Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104:3598-602. [PMID: 15315975 DOI: 10.1182/blood-2004-03-1107] [Citation(s) in RCA: 162] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The antiphospholipid syndrome is characterized by the presence of antiphospholipid antibodies in plasma of patients with thromboembolic complications. A major problem in defining the syndrome is that serologic assays to detect antiphospholipid antibodies have a low specificity. We recently published a method that specifically detects lupus anticoagulant (LAC) caused by anti–β2-glycoprotein I antibodies. Here, we studied the clinical relevance of detecting β2-glycoprotein I–dependent LAC. Plasma samples were collected from 198 patients with autoimmune diseases. In those samples with a positive partial thromboplastin time–lupus anticoagulant (PTT-LA), a modified activated partial thromboplastin time (aPTT)–based LAC test was performed with cardiolipin as confirming agent. Twenty-five of 58 patients with an aPTT-based LAC were dependent on the presence of anti–β2-glycoprotein I antibodies. Presence of β2-glycoprotein I–dependent LAC was almost completely associated with a history of thromboembolic complications (odds ratio, 42.3; 95% confidence interval, 194.3-9.9). An increased frequency of thrombosis was not found in 33 patients with LAC independent of anti–β2-glycoprotein I antibodies (odds ratio, 1.6; 95% confidence interval, 3.9-0.8). The use of an LAC assay with cardiolipin as confirming agent strongly improves the detection of patients at risk of thrombosis. Our findings suggest that anti–β2-glycoprotein I antibodies with LAC activity are antibodies that are responsible for the thromboembolic complications in the antiphospholipid syndrome.
Collapse
Affiliation(s)
- H Bas de Laat
- Department of Haematology, G03.647, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands
| | | | | | | | | |
Collapse
|
253
|
Oztürk MA, Haznedaroğlu IC, Turgut M, Göker H. Current debates in antiphospholipid syndrome: the acquired antibody-mediated thrombophilia. Clin Appl Thromb Hemost 2004; 10:89-126. [PMID: 15094931 DOI: 10.1177/107602960401000201] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Antiphospholipid (APL) syndrome is the most common form of acquired thrombophilia. It can cause significant morbidity and even mortality. The term "APL antibodies" represents a heterogeneous group of antibodies associated with this disorder. Currently no single assay can identify every APL antibody. Clinically relevant APL antibodies are mainly anticardiolipin antibodies (ACA) detected by solid phase enzyme-linked immunosorbent assay (ELISA) and lupus anticoagulants (LA) demonstrated by in vitro coagulation assay. However, there are some other antibodies associated with the APL syndrome (i.e., subgroup APL antibodies). ACAs, LAs, and subgroup APL antibodies represent intersecting, but non-identical, subsets of autoantibodies. Thus, those autoantibodies may coexist or may occur independently. Any organ system and any size of vessel can be affected during the clinical course of the disease. Therefore, the APL syndrome can manifest itself in a wide variety of clinical thrombotic features. Fetal loss and pregnancy morbidity represent a specific challenge. Despite tremendous advances in the understanding of the pathogenesis of APL syndrome during the past decade, the mainstay of management is still anticoagulation. However, there is no general agreement regarding the duration and intensity of anti-coagulant therapy. In this review, we focused on the current dilemmas and their present clarifications in the wide clinicopathologic spectrum of APL syndrome and APL antibody-related distinct pathologic conditions.
Collapse
Affiliation(s)
- M Akif Oztürk
- Gazi University School of Medicine Department of Rheumatology, Ankara, Turkey.
| | | | | | | |
Collapse
|
254
|
Obermoser G, Bitterlich W, Kunz F, Sepp NT. Clinical Significance of Anticardiolipin and Anti-β 2-Glycoprotein I Antibodies. Int Arch Allergy Immunol 2004; 135:148-53. [PMID: 15345914 DOI: 10.1159/000080658] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2004] [Accepted: 06/24/2004] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Anticardiolipin (aCl) and anti-beta2-glycoprotein I (anti-beta2-gpI) antibodies are autoantibodies associated with the antiphospholipid syndrome (APS), which is characterized by both arterial and venous thrombosis and miscarriages. The scope of this study was to explore the clinical characteristics of patients with aCl and anti-beta2-gpI antibodies. METHODS ACl were tested in 3,600 consecutive sera in our laboratory between January 1999 and June 2001. The clinical diagnosis and prevalence of thrombosis and pregnancy morbidity were retrospectively reviewed in aCl-positive patients. Furthermore, the frequency of anti-beta2-gpI antibodies, lupus anticoagulant (LA), prolonged activated partial thromboplastin time (aPTT), and thrombocytopenia were investigated in aCl-positive patients. RESULTS 147 aCl-positive patients, 110 women and 37 men with a mean age of 41 years (range 7.8-82.5), were identified. 42 (28.6%) aCl-positive patients fulfilled the criteria for APS which was secondary to a connective tissue disorder in 8 patients. The frequency of anti-beta2-gpI antibodies and LA, prolonged aPTT, and thrombocytopenia in aCl-positive patients was 23.8, 27.2, 25.7 and 9.2%, respectively. The presence of both aCl and anti-beta2-gpI antibodies was strongly associated with clinical symptoms of APS (p = 0.007) compared to p = 0.008 for LA. CONCLUSION Our data suggest that assessment of anti-beta2-gpI antibodies in addition to aCl is a valuable diagnostic tool in the workup of patients with APS.
Collapse
Affiliation(s)
- Gerlinde Obermoser
- Department of Dermatology, University Hospital of Innsbruck, Innsbruck, Austria.
| | | | | | | |
Collapse
|
255
|
|
256
|
Bevers EM, Zwaal RFA, Willems GM. The effect of phospholipids on the formation of immune complexes between autoantibodies and β2-glycoprotein I or prothrombin. Clin Immunol 2004; 112:150-60. [PMID: 15240158 DOI: 10.1016/j.clim.2004.02.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2004] [Accepted: 02/27/2004] [Indexed: 11/19/2022]
Abstract
In the last decennium, it became clear that antiphospholipid antibodies found in patients with antiphospholipid syndrome (APS) are in fact antibodies against lipid-bound plasma proteins. The most frequently occurring antigens are beta2-glycoprotein I and prothrombin, although several other lipid-bound plasma proteins have been reported as antigen for antiphospholipid antibodies. Both proteins bind to anionic phospholipids, mainly phosphatidylserine, which becomes exposed at the surface of activated platelets, apoptotic cells, or cell-derived microparticles. The binding of beta2-glycoprotein I and prothrombin to these cell surfaces or to artificial lipid vesicles with comparable amounts of anionic phospholipids is rather weak. Antiphospholipid antibodies from patients are predominantly of low affinity regarding their interaction with beta2-glycoprotein I or prothrombin in solution. In the presence of a suitable phospholipid surface, however, this interaction is strongly enhanced. There is now strong evidence that formation of bivalent, trimolecular immune complexes at the lipid membrane essentially contributes to the binding of these intrinsically low affinity patient antibodies. Depending on the affinity, the epitope specificity, and the polyclonality of a particular IgG preparation, multimeric structures of lipid-bound immune complexes may form a lattice with multiple interactions on the lipid (cell) surface. It is hypothesized that the functional activity, that is, the ability of antibodies to interfere with lipid-dependent reactions, not only depends on their affinity for the antigen, but also on their ability to form multiple interconnected bivalent trimolecular complexes at the lipid (or cell) surface. It is further proposed that the rate of desorption of immune complexes may present a better indicator for the functional properties of the antibodies than the amount of adsorbed immune complexes.
Collapse
Affiliation(s)
- Edouard M Bevers
- Cardiovascular Research Institute Maastricht, University of Maastricht, The Netherlands.
| | | | | |
Collapse
|
257
|
Bas de Laat H, Derksen RHWM, de Groot PG. β2-Glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol 2004; 112:161-8. [PMID: 15240159 DOI: 10.1016/j.clim.2004.02.012] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2004] [Accepted: 02/27/2004] [Indexed: 11/24/2022]
Abstract
From its discovery in the early 60s till the beginning of the 90s, there was not much interest in plasma protein beta2-glycoprotein I (beta2-GPI). The finding that beta2-GPI acts as an essential cofactor for the detection of antiphospholipid antibodies (aPL) tremendously increased the interest in beta2-GPI [Lancet 335 (1990) 1544; Lancet 336 (1990) 177; Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 4120]. It is now generally accepted that autoantibodies directed towards beta2-GPI are not only a serological marker but that they are involved in the pathology of the antiphospholipid syndrome (APS). In this review, we will first discuss the biochemistry of the protein beta2-GPI and the influence that the antibodies have on the function of beta2-GPI. Next, we will discuss the problems that are faced when assays to detect the presence of the autoantibodies are performed, emphasizing the urgent need for standardization of the anti-beta2-GPI-ELISA. Finally, we will discuss our latest insights into beta2-GPI and its role in the pathology of APS. Thereby, we will focus on the role of dimerized beta2-GPI on platelet and endothelial cell function.
Collapse
Affiliation(s)
- H Bas de Laat
- Department of Haematology, Thrombosis and Haemostasis Laboratory, University Medical Center Utrecht, The Netherlands
| | | | | |
Collapse
|
258
|
Nash MJ, Camilleri RS, Kunka S, Mackie IJ, Machin SJ, Cohen H. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost 2004; 2:1077-81. [PMID: 15219190 DOI: 10.1111/j.1538-7836.2004.00810.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The importance of testing for anticardiolipin antibodies (aCL) in the diagnosis of antiphospholipid syndrome (APS) in patients with thrombosis has recently been challenged (ISTH SSC meeting, Boston 2002). We have analyzed the antiphospholipid serology of 123 patients with persistent antiphospholipid antibodies (aPL) attending our hematology department. The cohort was tested for anti-beta(2)-glycoprotein I (beta(2)-GPI) antibodies and aCL of IgG and IgM class and for lupus anticoagulant (LA). Ninety-six of these patients fulfilled Sapporo clinical criteria for APS and 70 of these patients had venous and/or arterial thrombosis. Patients with LA plus anti-beta(2)-GPI antibodies had significantly higher levels of IgG aCL and anti-beta(2)-GPI antibodies than those exhibiting positivity for only LA or anti-beta(2)-GPI antibodies (P < 0.05). Patients with aCL IgG levels over 60 GPLU were found in all cases to be positive for LA and anti-beta(2)-GPI antibodies; 25.2% (31/123) of all patients and 26.04% (25/96) of patients fulfilling Sapporo clinical criteria for APS were positive for aCL only. The mean IgG aCL level in the Sapporo clinical criteria positive patients who had aCL only was 11.5 GPLU (normal < 5 GPLU). These data indicate that omission of aCL testing from the clinical investigation of APS could lead to a failure to diagnose the syndrome in a proportion of patients.
Collapse
Affiliation(s)
- M J Nash
- Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
| | | | | | | | | | | |
Collapse
|
259
|
de Moerloose P, Reber G. Antiphospholipid antibodies: do we still need to perform anticardiolipin ELISA assays? J Thromb Haemost 2004; 2:1071-3. [PMID: 15219188 DOI: 10.1111/j.1538-7836.2004.00811.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- P de Moerloose
- Division of Angiology and Hemostasis, University Hospital, Geneva, Switzerland.
| | | |
Collapse
|
260
|
|
261
|
de Groot PG, Derksen RHWM. Antiphospholipid antibodies: update on detection, pathophysiology, and treatment. Curr Opin Hematol 2004; 11:165-9. [PMID: 15257015 DOI: 10.1097/01.moh.0000130313.95291.4a] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW The antiphospholipid syndrome is a noninflammatory disease characterized by the presence of antiphospholipid antibodies in the plasma of patients with venous or arterial thrombosis or obstetric complications. Understanding of the pathology of the syndrome is only rudimentary and no physician can pretend that treatment is adequate. It is not possible to identify patients with the syndrome for certain. This paper reviews the substantial and promising headway made in the past year. RECENT FINDINGS It has become clear that lupus anticoagulant is the assay of choice to detect the syndrome and that antibodies directed towards beta2Glycoprotein 1 are the clinical relevant autoantibodies. These antibodies are able to activate a number of cells involved in the regulation of hemostasis. SUMMARY The latest developments will make it soon possible to define patient with the syndrome unambiguously. This is absolutely necessary to understand why the presence of antiphospholipid antibodies cause an increased thrombotic risk.
Collapse
Affiliation(s)
- Philip G de Groot
- Departments of Haematology and Rheumatology & Clinical Immunology, University Medical Centre, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
| | | |
Collapse
|
262
|
Abstract
There is increased scientific interest in the diagnosis of the antiphospholipid syndrome (APS), as therapeutic interventions can lead to substantial improvement in clinical outcome. As the clinical features of APS are far from specific, a sound laboratory method is needed to support or exclude the diagnosis. Two methods are currently used for the diagnosis of APS: (1). ELISA-based immunoassays for the detection of anticardiolipin (aCL) antibodies; and (2). clotting assays for determination of the lupus anticoagulant (LA). However, the first method is limited by a low specificity, and the second by low sensitivity. Furthermore, for both methods standardisation is unsatisfactory. Therefore, a number of new assays have been proposed as alternative or supplementary to aCL and LA tests. These include the anti-beta-2-glycoprotein I or antiprothrombin ELISAs, an ELISA utilising a phospholipid mixture, clotting assays with varying activators and assays utilising chromogenic substrates. This review presents a brief outline of APS, the autoantibodies associated with this syndrome, the basic principles of the standard assays used and a description of newer methods currently being validated.
Collapse
Affiliation(s)
- Freda Passam
- Department of Immunology, Allergy and Infectious Disease, St George Hospital, University of New South Wales, Australia
| | | |
Collapse
|
263
|
Reber G, de Moerloose P. Anti-β2-glycoprotein I antibodies—When and how should they be measured? Thromb Res 2004; 114:527-31. [PMID: 15507287 DOI: 10.1016/j.thromres.2004.06.034] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2004] [Revised: 06/17/2004] [Accepted: 06/23/2004] [Indexed: 11/24/2022]
Abstract
The biological criteria of the antiphospholipid syndrome defined at the Sapporo meeting in 1998 included the presence of lupus anticoagulant (LA) and/or anticardiolipin antibodies at medium and high titers. During the 48th SSC meeting held in Boston July 2002, it was proposed to modify these criteria. Four patient groups were defined, the first one comprising LA and anti-beta2glycoprotein I antibodies (abeta2GPI), the second one LA only, the third one abeta2GPI only and the fourth one other antiphospholipid antibodies such as antiprothrombin, anticardiolipin, antiphosphatidylethanolamine, etc. This proposition raised the issue of the association of abeta2GPI with APS clinical criteria (thrombosis and pregnancy morbidity). In some studies, a strong association between IgG abeta2GPI and thrombosis was found, whereas in others this association could not be demonstrated. In the obstetrical field, few studies are available and no clear conclusion can be drawn yet. However, for thrombosis or pregnancy morbidity, it has been shown that in up to 10% of patients, abeta2GPI are the sole antibodies present and therefore the diagnosis of APS would be missed in these patients. In addition, some studies suggest that the severity of disease is dependent on the number of positive tests and on their titers. We recommend abeta2GPI assays to be included in the panel of antiphospholipid screening tests. However, the standardisation of abeta2GPI assays has to be improved in order to ensure better comparability between the studies.
Collapse
Affiliation(s)
- Guido Reber
- Division of Angiology and Haemostasis, University Hospital, Geneva, Switzerland.
| | | |
Collapse
|
264
|
Cockerill KA, Iverson GM, Jones DS, Linnik MD. Therapeutic Potential of Toleragens in the Management of Antiphospholipid Syndrome. BioDrugs 2004; 18:297-305. [PMID: 15377172 DOI: 10.2165/00063030-200418050-00002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Autoantibodies to beta2-glycoprotein I (beta2GPI) are believed to be the primary cause of coagulation abnormalities in patients with antiphospholipid syndrome (APS). Clinical features include a range of life-threatening thrombotic events and microangiopathies affecting multiple organ systems. Current standard of care relies on long-term, high-intensity anticoagulation and is associated with a high risk for serious bleeding events. The relation between autoantibodies and the pathophysiology of APS is not clearly understood, but numerous in vitro studies have characterized the effects of antiphospholipid autoantibodies on various components of the coagulation cascade, including tissue factor and the protein C pathway. The fine specificity of autoantibodies to beta2GPI is a subject of considerable debate; however, a body of evidence may offer resolution by integrating concepts of antibody affinity and assay sensitivity with carefully designed molecular studies. An investigational new therapy for APS is based on the approach that pathogenic antibodies may be reduced via depletion of circulating autoantibodies and induction of immune tolerance at the B-cell level. Preliminary results from a phase I/II clinical trial with LJP 1082, a B-cell toleragen, indicate the drug was well tolerated and may warrant further development for reduction of thrombotic events in patients with APS.
Collapse
|
265
|
Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P, Boffa MC. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114:553-8. [PMID: 15507291 DOI: 10.1016/j.thromres.2004.06.035] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2004] [Revised: 06/20/2004] [Accepted: 06/23/2004] [Indexed: 10/26/2022]
Abstract
Antiphospholipid ELISAs are part of the Antiphospholipid Antibodies Syndrome classification criteria, having the same diagnostic value as lupus anticoagulant. However, sometimes their results appear scarcely meaningful especially when wide metanalyses studies are performed, probably because of their well-known inter-laboratory variability. The application of a common protocol was shown to improve the test reproducibility, but this observation did not have any influence on the routine performances. After discussion among experts at the European level, we identified four conditions named "minimal requirements" considered useful to decrease the inter-laboratory variability: (1) to run the samples in duplicate; (2) to determine the cut off level in each laboratory analysing at least 50 samples from normal subjects, possibly age- and sex-matched with the patient population usually attending the Centre; (3) to calculate the cut-off level in percentiles; (4) to use stable external control in the tests. A collaborative study involving 36 European centres proved that the use of monoclonal anti-beta2 glycoprotein I antibodies, HCAL (IgG) and EY2C9 (IgM) as standards, can help to reduce the inter-laboratory coefficient of variation both in anticardiolipin (aCL) and anti-beta2GPI (anti-beta2 glycoprotein I) ELISA. Therefore, we propose HCAL and EY2C9 as external controls, but other monoclonal or polyclonal preparations may be considered. During an interactive workshop held last May in Italy, 16 companies producing these tests agreed to consider the introduction of the "requirements" in their products. We suggest to adopt these "requirements" particularly in clinical studies, in order to compare more easily the literature data.
Collapse
Affiliation(s)
- Angela Tincani
- Rheumatology and Clinical Immunology, Ospedale Civile di Brescia, Piazza Spedali Civili 1, 25125 Brescia, Italy.
| | | | | | | | | | | | | |
Collapse
|